DP121 | POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE AND ANTI-CD38 MONOCLONAL ANTIBODIES: REAL WORLD SHORT-LIVED RESPONSES DRIVEN BY DOUBLE REFRACTORINESS

Background: Drug refractoriness adversely impacts outcomes in relapsed/refractory multiple myeloma (MM) patients (pts). Increased frontline use of lenalidomide (Len) and anti-CD38 monoclonal antibodies (MoAbs) led to a growing number of pts double refractory (DR) after 1 or 2 lines of therapy (LoT)...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	C. Liberatore, P. Tacchetti, C. Conticello, G. Barilà, E. Antonioli, A. Belotti, A.M. Cafro, L. Paris, V. Bongarzoni, M. Gentile, M. Da Vià, M. Quaresima, S. Pezzatti, F. Ciambelli, M. Garzia, O. Annibali, F. Fazio, G. Antolino, N. Sgherza, F. Farina, A. Citro, M. Galli, V. Del Fabro, C.S. Cartia, F. Fioritoni, K Mancuso, I. Attucci, M.L. Pioltelli, M. Puppi, S. Terlizzi, C. Lisi, M. Palumbo, V.V. Ferretti, S. Morè, M.T. Petrucci, S. Mangiacavalli
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2025-09-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/12627
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!